Agilex Biolabs Pty
Agilex Biolabs Pty is recorded as a service provider in 14 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 14 of 14 trials · Latest update first
A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin Versus Sapropterin in Participants With Phenylketonuria ≥2 Years of Age
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Of 82 enrolled participants tested for sepiapterin responsiveness in Part 1, 62 were randomized for Part 2; 15 were nonresponders and 5 did not meet Part 1 eligibility criteria.
- Protocol amendments modified eligibility criteria, ultimately specifying exclusion of incapacitated adults, and clarified the primary analysis set and efficacy-endpoint analyses.
- Protocol amendments clarified Part 1 and Part 2 washout periods, dietary-control observation duration, and added a +1-day window for virtual visits.
- Enrollment of participants with biochemically diagnosed classical PKU was capped at 30% of the safety analysis set.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients
Sponsor Satellos Bioscience Inc.
- Start (EU)
- Latest update
- Estimated end
A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies
Sponsor Grey Wolf Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Sponsor Adarx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.
Sponsor Nura Bio Inc.
- Start (EU)
- Latest update
- Estimated end
A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)
Sponsor Dimerix Bioscience Pty Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients with Spinal and Bulbar Muscular Atrophy (SBMA)
Sponsor Nido Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease
Sponsor Skyhawk Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME
Sponsor Biocryst Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer)
Sponsor Pathios Therapeutics Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndrome
Sponsor Harmony Biosciences Management Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults with Fragile X Syndrome - RECONNECT
Sponsor Harmony Biosciences Management Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab.
Sponsor Aslan Pharmaceuticals Pte Ltd
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Agilex Biolabs Pty?
The 2026-10-09 snapshot links Agilex Biolabs Pty to 14 distinct CTIS trials. Recorded services include Laboratory services, PK, PK and biomarker analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Agilex Biolabs Pty?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Allergy, Gastroenterology, Gynecology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Agilex Biolabs Pty conducted?
The linked trials record locations in 16 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where Agilex Biolabs Pty delivered services.
What can this page tell me about Agilex Biolabs Pty's trial experience?
Browse 14 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Agilex Biolabs Pty. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Agilex Biolabs Pty Limited